State Street’s AYTU BioPharma AYTU Stock Holding History

State Street’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,884	Closed	-$18.5K	–	4790
2022 Q4	$18.5K	Hold	4,884	–	–	﹤0.01%	4742
2022 Q3	$18K	Hold	4,884	–	–	﹤0.01%	4843
2022 Q2	$67K	Hold	4,884	–	–	﹤0.01%	4659
2022 Q1	$105K	Hold	4,884	–	–	﹤0.01%	4626
2021 Q4	$132K	Hold	4,884	–	–	﹤0.01%	4506
2021 Q3	$281K	Hold	4,884	–	–	﹤0.01%	4227
2021 Q2	$489K	Sell	4,884 -3,982	-45%	-$467K	﹤0.01%	3863
2021 Q1	$1.35M	Buy	8,866 +6,402	+260%	+$1.02M	﹤0.01%	3565
2020 Q4	$295K	Buy	2,464 +1,014	+70%	+$185K	﹤0.01%	3706
2020 Q3	$345K	Buy	1,450 +303	+26%	+$77.9K	﹤0.01%	3612
2020 Q2	$326K	Buy	+1,147	New	+$347K	﹤0.01%	3582

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

State Street's AYTU Position: Q1 2023 in Review

State Street sold out of AYTU BioPharma (AYTU) in Q1 2023, closing a stake of 4,884 shares — an estimated $18.5K sold.

State Street first reported a position in AYTU in Q2 2020 and held it in 11 quarters. The position peaked at $1.35M in Q1 2021. 21 funds tracked by Wall St. Rank hold AYTU as of Q1 2023.

State Street reported no remaining AYTU BioPharma position as of Q1 2023 after selling out during the quarter.
State Street sold 4,884 AYTU BioPharma shares in Q1 2023, an estimated $18.5K.
State Street first reported a position in AYTU BioPharma in Q2 2020 and held it in 11 quarters.
State Street's AYTU BioPharma position peaked at $1.35M in Q1 2021.
21 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.